Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

by Fernando C Fervenza, Roser Torra, David G Warnock
Published 2008-11-01

Current and Investigational Therapeutics for Fabry Disease

by Andrew Felis, Michael Whitlow, Abigayle Kraus, David G. Warnock, Eric Wallace
Published 2020-04-01

Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease.

by Aurelie Nguyen Dinh Cat, Brigitte Escoubet, Vincent Agrapart, Violaine Griol-Charhbili, Trenton Schoeb, Wenguang Feng, Edgar Jaimes, David G Warnock, Frederic Jaisser
Published 2012-01-01

High-sensitivity C-reactive protein and risk of sepsis.

by Henry E Wang, Nathan I Shapiro, Monika M Safford, Russell Griffin, Suzanne Judd, Joel B Rodgers, David G Warnock, Mary Cushman, George Howard
Published 2013-01-01

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.

by Sachie Nakano, Takahiro Tsukimura, Tadayasu Togawa, Toya Ohashi, Masahisa Kobayashi, Katsuyoshi Takayama, Yukuharu Kobayashi, Hiroshi Abiko, Masatsugu Satou, Tohru Nakahata, David G Warnock, Hitoshi Sakuraba, Futoshi Shibasaki
Published 2015-01-01

A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

by Andreas D Kistler, Justyna Siwy, Frank Breunig, Praveen Jeevaratnam, Alexander Scherl, William Mullen, David G Warnock, Christoph Wanner, Derralynn A Hughes, Harald Mischak, Rudolf P Wüthrich, Andreas L Serra
Published 2011-01-01

Dietary Oxidative Balance Scores and Biomarkers of Inflammation among Individuals with and without Chronic Kidney Disease

by Kristin J. Marks, Terryl J. Hartman, Suzanne E. Judd, Titilayo O. Ilori, Katharine L. Cheung, David G. Warnock, Orlando M. Gutiérrez, Michael Goodman, Mary Cushman, William M. McClellan
Published 2018-08-01

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.

by David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J Flanagan, Brandon A Wustman, Jay Barth, Carrolee Barlow, Kenneth J Valenzano, David J Lockhart, Pol Boudes, Franklin K Johnson
Published 2015-01-01